Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications

Significance of the topic

Glycosylation affects more than half of human proteins and influences folding, stability, activity, trafficking and immune recognition. Altered glycan structures are hallmarks of oncogenic transformation, tumor invasion and metastasis. Comprehensive profiling of plasma glycoproteins and their glycan modifications offers insights into disease mechanisms and supports biomarker discovery and therapeutic targeting.

Objectives and study overview

The study aimed to establish an integrated mass spectrometry platform for plasma glycoproteomics. It combined intact protein fractionation with peptide-level analysis to identify glycoproteins, map glycosylation sites and characterize oligosaccharide compositions. The workflow was applied to human plasma to demonstrate depth, sensitivity and heterogeneity profiling.

Methodology and instrumentation

The workflow comprised four major steps:

• Immunodepletion of abundant plasma proteins to enrich low‐abundance fraction
• Online two‐dimensional high‐performance liquid chromatography (2D‐HPLC) first by anion‐exchange then by reversed‐phase separation
• In‐solution tryptic digestion followed by hydrophilic interaction chromatography (HIC) enrichment of glycopeptides
• Dual mass spectrometric analysis: LC‐ESI MS/MS on an LTQ-FT instrument for protein identification and offline LC‐MALDI‐DIT MS/MS for glycopeptide characterization

Used instrumentation

• Shimadzu 2D‐HPLC system with online anion‐exchange and reversed‐phase columns
• AccuSpot nano‐scale MALDI plate spotter
• Hydrophilic interaction chromatography resin (Sepharose HIC)
• LTQ‐FT mass spectrometer for LC‐ESI MS/MS
• In‐house built MALDI‐DIT tandem MS for offline peptide and glycopeptide analysis

Main results and discussion

The combined approach identified 64 plasma proteins with high confidence; 30 were annotated as glycoproteins in UniProt. MALDI‐DIT analysis characterized 34 glycoproteins and confirmed 24 UniProt annotations. Detailed mapping revealed extensive microheterogeneity: single glycosylation sites carried multiple distinct glycans. Examples include complement factor I and C4b‐binding protein β chain peptides each modified by at least two different glycan compositions, and α-1-acid glycoprotein displaying six unique glycoforms. This underscores the method’s ability to resolve site‐specific glycan diversity.

Benefits and practical applications

• Simultaneous elucidation of peptide sequence, glycosylation sites and glycan structures in complex mixtures
• High sensitivity for low‐abundance plasma glycoproteins
• Potential for discovery and validation of glycoform‐based biomarkers in cancer and other diseases
• Applicability to quality control in biopharmaceutical development and monitoring of therapeutic glycoproteins

Future trends and potential applications

Advances may include higher throughput fractionation, integration of quantitative labeling strategies, improved glycan structural assignments via advanced fragmentation methods and data analytics. Expansion to diverse biofluids and large clinical cohorts could accelerate identification of disease‐specific glycosylation signatures. Machine learning integration may enhance pattern recognition of glycoform changes.

Conclusion

The integrated mass spectrometry platform effectively profiles plasma glycoproteins and resolves glycan microheterogeneity. Its dual MS detection and comprehensive workflow provide robust tools for biomarker discovery and therapeutic monitoring, with broad potential across biomedical research and clinical proteomics.

References

1. Wang H et al. Mol Cell Proteomics. 2005;4:618–625.
2. Fukuyama Y et al. Anal Chem. 2008;80:2171–2179.
3. Wang H et al. Nat Protoc. 2011;6:253–269.
4. Wada Y et al. Anal Chem. 2004;76:6560–6565.